It was found that the prescription for the injection-type obesity treatment "Saxenda" through non-face-to-face treatment increased 18 times from the end of last year.
According to data from the Health Insurance Review and Assessment Service received by Jeon Jin-sook of the Democratic Party of Korea of the National Assembly's Health and Welfare Committee, the number of Saxenda prescriptions using non-face-to-face treatment increased 18.3 times from 183 in December last year to 3,347 last month.
During the same period, the number of face-to-face prescriptions increased only 1.1 times from 25,562 to 14,729.
In February, the government allowed non-face-to-face treatment of first-time patients and medical institutions above the hospital level to fill the resignation gap of majors.
Lawmaker Jeon Jin-sook urged measures to be prepared, saying that non-face-to-face treatment, which is operated in the form of a pilot project, is leading to non-essential over-treatment.
※ 'Your report becomes news'
[Kakao Talk] YTN Search and Add Channel
[Phone] 02-398-8585
[Mail] social@ytn.co.kr
[Copyright holder (c) YTN Unauthorized reproduction, redistribution and use of AI data prohibited]